MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY

Their core work

MHRA is the UK's national medicines regulator, responsible for ensuring that drugs, medical devices, and vaccines meet safety, quality, and efficacy standards. Within EU research, they contribute regulatory expertise to projects on pharmacovigilance, drug safety monitoring, vaccine development infrastructure, and medicine identification standards. Their role is to bring the regulator's perspective into research consortia — helping projects design outputs that meet real-world approval and compliance requirements.

What they specialise in

How they've shifted over time

MHRA's earliest H2020 involvement (2018–2019) centred on core regulatory science — training academics in regulatory processes (STARS) and leading web-based adverse drug reaction monitoring (WEB-RADR 2). From 2019 onward, their focus broadened significantly into applied domains: pregnancy pharmacovigilance, digital medicine identification standards (IDMP), cross-border eHealth, and vaccine infrastructure. The trajectory shows a shift from foundational regulatory capacity-building toward embedding regulatory expertise in specific health technology domains.

MHRA is increasingly embedding regulatory know-how into vaccine innovation and digital health standards, making them a valuable partner for projects needing regulatory pathway guidance.

How they like to work

MHRA primarily joins consortia as a participant rather than leading them — they coordinated only 1 of 7 projects (WEB-RADR 2). With 197 unique partners across 29 countries, they operate as a specialist contributor within large, multi-national consortia. Their value to these consortia is clear: they bring the regulatory authority's perspective, which is essential for projects aiming at market-ready health solutions.

MHRA has collaborated with 197 distinct partners across 29 countries, reflecting a broad European and international network typical of large health research consortia. Their connections span academia, industry, and other regulatory bodies across the EU.

What sets them apart

MHRA is not a research lab or university — it is the UK's actual medicines regulator participating in research projects. This gives consortia direct access to the regulatory mindset and compliance requirements that will determine whether a health innovation reaches the market. For any project dealing with drug safety, vaccine approval pathways, or digital health standards, having a national regulatory agency as a partner adds credibility and practical regulatory insight that academic partners simply cannot provide.

Highlights from their portfolio

• WEB-RADR 2
  MHRA's only coordinated project (EUR 712,500) — their flagship effort in web-based pharmacovigilance and adverse drug reaction monitoring.
• Inno4Vac
  Largest participation budget (EUR 535,801) and longest-running project (2021–2027), signalling a sustained commitment to vaccine innovation.
• ConcePTION
  Addresses a critical gap in medication safety for pregnant women, combining pharmacovigilance with predictive models and biobanking.